Novilytic

Executive Summary

Novilytic is a privately-held biochemistry analytics company founded in 2019 and headquartered in Cambridge, MA, with an operational facility in West Lafayette, IN. The company has developed the Proteometer platform, a suite of consumable kits that enable rapid, near-real-time measurement of critical quality attributes (CQAs) for protein-based pharmaceuticals, such as monoclonal antibodies and bispecifics. The technology directly analyzes fermentation broth, eliminating extensive sample preparation and significantly accelerating process development and manufacturing monitoring. By addressing a key bottleneck in biopharma analytics, Novilytic’s platform has the potential to reduce costs and improve efficiency for drug developers. While the company has not disclosed total funding, its innovative approach positions it well in the growing bioprocess analytics market. The team’s focus on simplifying complex analytics through proprietary consumables differentiates it from traditional analytical methods and competing platforms. As the biopharmaceutical industry increasingly adopts Process Analytical Technology (PAT) and Quality by Design (QbD) initiatives, Novilytic’s real-time monitoring solution could become an essential tool for both established manufacturers and emerging biotechs.

Upcoming Catalysts (preview)

• Q3 2026Commercial partnership with a top biopharma manufacturer60% success
• Q4 2026Launch of next-generation Proteometer kit expanding CQA coverage70% success
• Q2 2026Series A funding round announcement50% success